Literature DB >> 3072925

Disposition of ceftazidime in surgical patients with intra-abdominal infection.

K L Heim-Duthoy1, M P Bubrick, D M Cocchetto, G R Matzke.   

Abstract

The disposition of ceftazidime was assessed in 11 surgical patients with suspected intra-abdominal infection. All patients had normal hepatic function, and creatinine clearances ranged from 43 to 186 ml/min. Patients received 2 g of ceftazidime intravenously every 8 h. Trough and peak concentrations in serum were measured on day 2, and trough and postdose concentrations in serum were determined on 10 samples collected during a dosage interval between days 3 and 6 of therapy. Ceftazidime peak and trough concentrations in serum at steady state determined by high-performance liquid chromatography were 257.4 +/- 122.0 (mean +/- standard deviation) and 13.1 +/- 20.6 mg/liter. The serum-concentration-versus-time profile was multiexponential. The elimination half-life, steady-state volume of distribution, and total body clearance were 2.52 +/- 1.39 h, 0.31 +/- 0.12 liter/kg, and 0.11 +/- 0.05 liter/h per kg, respectively. Total predicted body clearance significantly correlated with the measured values (r = 0.868; P = 0.001). The disposition of ceftazidime is dependent on creatinine clearance and is not significantly altered by surgery or acute infectious processes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3072925      PMCID: PMC176030          DOI: 10.1128/AAC.32.12.1845

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency.

Authors:  G R Matzke; J Yeh; W M Awni; C E Halstenson; M Chung
Journal:  Ann Allergy       Date:  1987-12

2.  Pharmacokinetics of ceftazidime in normal and uremic subjects.

Authors:  A Leroy; F Leguy; F Borsa; G R Spencer; J P Fillastre; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

3.  High-pressure liquid chromatographic analysis of ceftazidime in serum and urine.

Authors:  J S Leeder; M Spino; A M Tesoro; S M MacLeod
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  Ceftazidime: pharmacokinetics in patients and effects on the renal function.

Authors:  S R Norrby; L A Burman; H Linderholm; B Trollfors
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

5.  Pharmacokinetics of ceftazidime in patients with renal insufficiency.

Authors:  L S Welage; R W Schultz; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

Review 6.  Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime.

Authors:  L O Gentry
Journal:  Pharmacotherapy       Date:  1985 Sep-Oct       Impact factor: 4.705

Review 7.  Current concepts in clinical therapeutics: intra-abdominal infections.

Authors:  J T DiPiro; J A Mansberger; J B Davis
Journal:  Clin Pharm       Date:  1986-01

8.  Pharmacokinetics of ceftazidime in normal and impaired renal function.

Authors:  D Höffler; P Koeppe; K J Williams
Journal:  Arzneimittelforschung       Date:  1984

9.  Multiple-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects.

Authors:  E A Swabb; A A Sugerman; D N McKinstry
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

10.  Pharmacokinetics of aztreonam in patients with gram-negative infections.

Authors:  D M Janicke; R F Cafarell; S W Parker; M A Apicella; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

View more
  3 in total

1.  Crossover assessment of serum bactericidal activity and pharmacokinetics of five broad-spectrum cephalosporins in the elderly.

Authors:  R G Deeter; M P Weinstein; K A Swanson; J S Gross; L C Bailey
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Pharmacokinetics of cefepime in patients with respiratory tract infections.

Authors:  J M Kovarik; J C ter Maaten; C M Rademaker; M Deenstra; I M Hoepelman; H C Hart; G R Matzke; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

3.  Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.

Authors:  Alan J Xiao; Benjamin W Miller; Jennifer A Huntington; David P Nicolau
Journal:  J Clin Pharmacol       Date:  2015-08-25       Impact factor: 3.126

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.